Neuraxis (NRXS) Interest Expenses (2022 - 2026)
Neuraxis (NRXS) posted Interest Expenses of $61082.0 for Q1 2026, up 282.45% sequentially from -$33479.0 in Q4 2025, and up 2630.53% YoY from $2237.0 in Q1 2025.
Neuraxis (NRXS) Interest Expenses (2022 - 2026) Analysis & Trends
Neuraxis has reported Interest Expenses for 5 years, with the latest figure at $61082.0 in Q1 2026.
- Quarterly Interest Expenses rose 2630.53% year-over-year to $61082.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $61082.0 (up 2630.53% YoY) and the FY2025 annual result came in at $361132.0, down 37.76% from the prior year.
- Interest Expenses rose to $61082.0 in Q1 2026 per NRXS's latest filing, from -$33479.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $576901.0 in Q2 2024 and troughed at -$138104.0 in Q4 2024.
- A 5-year average of $100071.8 and a median of $51286.0 in 2022 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2024 and 2026: Interest Expenses slumped 10352.71% in 2024, then surged 2630.53% in 2026.
- Over 5 years, Interest Expenses stood at $41490.0 in 2022, then slumped by 96.75% to $1347.0 in 2023, then plunged by 10352.71% to -$138104.0 in 2024, then surged by 75.76% to -$33479.0 in 2025, then jumped by 282.45% to $61082.0 in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $61082.0, -$33479.0, and $29661.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 82.05 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 20.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 93.62 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -4.89 Mn |
| 10 | Neuraxis | 75.51 Mn | 67.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 288,781.00 |
| Jun 30, 2026 | 288,781.00 |
| Mar 31, 2026 | 61,082.00 |
| Mar 31, 2026 | 61,082.00 |
| Dec 31, 2025 | -33,479.00 |
| Dec 31, 2025 | -33,479.00 |
| Sep 30, 2025 | 29,661.00 |
| Sep 30, 2025 | 29,661.00 |
| Jun 30, 2025 | 374,580.00 |
| Jun 30, 2025 | 374,580.00 |
| Mar 31, 2025 | 2,237.00 |
| Mar 31, 2025 | 2,237.00 |
| Dec 31, 2024 | -138,104.00 |
| Dec 31, 2024 | -138,104.00 |
| Sep 30, 2024 | 64,676.00 |
| Sep 30, 2024 | 64,676.00 |
| Jun 30, 2024 | 576,901.00 |
| Jun 30, 2024 | 576,901.00 |
| Mar 31, 2024 | 26,560.00 |
| Mar 31, 2024 | 26,560.00 |